These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Postmarketing surveillance. Oleen MA Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449 [TBL] [Abstract][Full Text] [Related]
7. Contraceptive development and clinical trials. Fraser IS Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511 [TBL] [Abstract][Full Text] [Related]
8. Postmarketing surveillance of new drugs: I. Review of objectives and methodology. Wardell WM; Tsianco MC; Anavekar SN; Davis HT J Clin Pharmacol; 1979; 19(2-3):85-94. PubMed ID: 370159 [No Abstract] [Full Text] [Related]
9. Medicaid drug-event data: an emerging tool for evaluation of drug risk. Jones JK; Van de Carr SW; Rosa F; Morse L; LeRoy A Acta Med Scand Suppl; 1984; 683():127-34. PubMed ID: 6377830 [TBL] [Abstract][Full Text] [Related]
10. Regulatory framework for the availability and use of animal drugs in the United States. Modric S Vet Clin North Am Small Anim Pract; 2013 Sep; 43(5):1005-12. PubMed ID: 23890234 [TBL] [Abstract][Full Text] [Related]
11. Minimum acceptable requirements for introduction and marketing of drugs. Lasagna L Drugs; 1974; 7(6):409-13. PubMed ID: 4422210 [No Abstract] [Full Text] [Related]
12. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. McKee AE; Farrell AT; Pazdur R; Woodcock J Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212 [TBL] [Abstract][Full Text] [Related]
13. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development. Rivera DR; Hartzema AG Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725 [TBL] [Abstract][Full Text] [Related]
14. Role of postmarketing surveillance in contemporary medicine. Woodcock J; Behrman RE; Dal Pan GJ Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798 [TBL] [Abstract][Full Text] [Related]
15. An overview of drug development in the United States and current challenges. Moore SW South Med J; 2003 Dec; 96(12):1244-55; quiz 1256. PubMed ID: 14696877 [TBL] [Abstract][Full Text] [Related]
16. The contribution of epidemiology to the study of drugs. Porta MS; Hartzema AG Drug Intell Clin Pharm; 1987 Sep; 21(9):741-7. PubMed ID: 3308393 [TBL] [Abstract][Full Text] [Related]
17. Fesults of the failure to perform adequate preclinical studies before administering new drugs to humans. Nestor JO S Afr Med J; 1975 Feb; 49(8):287-90. PubMed ID: 47186 [No Abstract] [Full Text] [Related]
18. The marketing of a drug. Wolfe SM Health Med; 1982; 1(2):31-2. PubMed ID: 10257087 [No Abstract] [Full Text] [Related]
19. The FDA Safety and Innovation Act. Steinbrook R; Sharfstein JM JAMA; 2012 Oct; 308(14):1437-8. PubMed ID: 23047356 [No Abstract] [Full Text] [Related]
20. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. Qato DM; Alexander GC JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303 [No Abstract] [Full Text] [Related] [Next] [New Search]